Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emergent Biosolutions (EBS) just unveiled an update.
Emergent BioSolutions Inc. recently announced that the U.S. FDA has approved the expansion of the indication for its ACAM2000® vaccine, now including immunization against mpox disease for high-risk individuals. This comes on the heels of Emergent’s move to have the vaccine evaluated by the WHO for emergency use during the mpox outbreak.
Learn more about EBS stock on TipRanks’ Stock Analysis page.